Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Needham & Company LLC 

Pacira Pharmaceuticals diskutieren

Pacira Pharmaceuticals

WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Aktie / Pharmazeutika / Small Cap /

17,90 €
-1,11 %

Einschätzung Buy
Rendite (%) -8,49 %
Kursziel 53,05
Veränderung
Endet am 02.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,49 %
Kursziel 40,02
Veränderung
Endet am 02.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,90 %
Kursziel 38,93
Veränderung
Endet am 03.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,72 %
Kursziel 27,62
Veränderung
Endet am 25.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Truist Financial Co. from $45.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 39,65
Veränderung
Endet am 31.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 34,16
Veränderung
Endet am 31.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $42.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 34,20
Veränderung
Endet am 31.07.25

Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Raymond James from $41.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat